Trial record 1 of 1 for:
AMX-818-001
To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05356741 |
|
Recruitment Status :
Recruiting
First Posted : May 2, 2022
Last Update Posted : March 8, 2024
|
Sponsor:
Amunix, a Sanofi Company
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Sanofi ( Amunix, a Sanofi Company )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 9, 2026 |
| Estimated Study Completion Date : | August 16, 2027 |